ENTB still has the best near term revenue and market opportunities...BMSN huge Long term potential once through those clinicals. Koos is going to need lots of cash for clinicals. They aint cheap. Perhaps there will be a partnership to help fund those. Path for ENTB much shorter still with huge potential.
Good to see this move back up for both from last yr...was a bit PO'd at the time to say the least.